Mohammad Haghighi1, Saeed Khodakarami1, Leila Jahangard1, Mohammad Ahmadpanah1, Hafez Bajoghli2, Edith Holsboer-Trachsler3, Serge Brand4. 1. Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran. 2. Psychiatry & Psychology Research Center (PPRC), Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran; ASEAN Institute for Health Development, Mahidol University, Nakhonpathom, Thailand. 3. Psychiatric Hospital of the University of Basel, Center for Affective, Stress and Sleep Disorders (ZASS), Basel, Switzerland. 4. Psychiatric Hospital of the University of Basel, Center for Affective, Stress and Sleep Disorders (ZASS), Basel, Switzerland; Department of Sport and Health Science, Division of Sport Science, University of Basel, Basel, Switzerland. Electronic address: serge.brand@upkbs.ch.
Abstract
BACKGROUND: The administration of statins seems to be a promising new avenue in the treatment of patients suffering from major depressive disorder (MDD), though patients suffering from severe MDD remain unstudied in this respect. The aim of the present study was therefore to investigate, in a randomized double-blind clinical trial, the influence of adjuvant atorvastatin on symptoms of depression in patients with MDD. METHODS: A total of 60 patients suffering from MDD (mean age: 32.25 years; 53% males) received a standard medication of 40 mg/d citalopram. Next, patients were randomly assigned either to the atorvastatin group (20 mg/d) or to the placebo group. Blood lipid values were assessed at baseline and on completion of the study 12 weeks later. Experts rated depressive symptoms via Hamilton Depression Rating Scales (HDRS) at baseline and 3, 6 and 12 weeks later. RESULTS:HDRS scores decreased over time; the significant Time by Group interaction showed that symptoms of depression decreased more in the atorvastatin than in the placebo group. Compared to the placebo group, in the atorvastatin group cholesterol, triglyceride, and Low Density Lipids (LDL) significantly decreased, and High Density Lipids (HDL) significantly increased over time. HDRS scores and blood lipid values were generally not associated. CONCLUSIONS: The pattern of results suggests that adjuvant atorvastatin favorably influences symptoms of depression among patients with severe MDD. Given that after 12 weeks of monotherapy and adjuvant atorvastatin patients were still moderately to severely depressed, more powerful treatment algorithms such as augmentation and change of medication are highly recommended.
RCT Entities:
BACKGROUND: The administration of statins seems to be a promising new avenue in the treatment of patients suffering from major depressive disorder (MDD), though patients suffering from severe MDD remain unstudied in this respect. The aim of the present study was therefore to investigate, in a randomized double-blind clinical trial, the influence of adjuvant atorvastatin on symptoms of depression in patients with MDD. METHODS: A total of 60 patients suffering from MDD (mean age: 32.25 years; 53% males) received a standard medication of 40 mg/d citalopram. Next, patients were randomly assigned either to the atorvastatin group (20 mg/d) or to the placebo group. Blood lipid values were assessed at baseline and on completion of the study 12 weeks later. Experts rated depressive symptoms via Hamilton Depression Rating Scales (HDRS) at baseline and 3, 6 and 12 weeks later. RESULTS:HDRS scores decreased over time; the significant Time by Group interaction showed that symptoms of depression decreased more in the atorvastatin than in the placebo group. Compared to the placebo group, in the atorvastatin group cholesterol, triglyceride, and Low Density Lipids (LDL) significantly decreased, and High Density Lipids (HDL) significantly increased over time. HDRS scores and blood lipid values were generally not associated. CONCLUSIONS: The pattern of results suggests that adjuvant atorvastatin favorably influences symptoms of depression among patients with severe MDD. Given that after 12 weeks of monotherapy and adjuvant atorvastatinpatients were still moderately to severely depressed, more powerful treatment algorithms such as augmentation and change of medication are highly recommended.
Authors: Christian Otte; Woo Ri Chae; Jan Nowacki; Michael Kaczmarczyk; Dominique Piber; Stefan Roepke; Stefanie Märschenz; Sandra Lischewski; Sein Schmidt; Barbara Ettrich; Hans Joergen Grabe; Ulrich Hegerl; Kim Hinkelmann; Tobias Hofmann; Deborah Janowitz; Klaus Junghanns; Kai G Kahl; Jan Philipp Klein; Tillmann H C Krueger; Gregor Leicht; David Prvulovic; Andreas Reif; Daniel Schoettle; Maria Strauss; Anna Westermair; Tim Friede; Stefan M Gold Journal: BMJ Open Date: 2020-12-01 Impact factor: 2.692
Authors: S W Kim; K Y Bae; J M Kim; I S Shin; Y J Hong; Y Ahn; M H Jeong; M Berk; J S Yoon Journal: Transl Psychiatry Date: 2015-08-18 Impact factor: 6.222
Authors: Beatrice Bortolato; Kamilla W Miskowiak; Cristiano A Köhler; Michael Maes; Brisa S Fernandes; Michael Berk; André F Carvalho Journal: BMC Med Date: 2016-01-22 Impact factor: 8.775